Sale of treasury shares: Santhera receives CHF 13,4 million

Santhera Pharmaceuticals announced that it completed the sale of 200'000 registered shares of common stock at an average price of CHF 66.85 per share. According to a press release received the company CHF 13,4 million in gross proceeds from the sale. The shares were sold by an independent broker within a period of one month. The new capital provides the company with headquarters in Liestal with sufficient funds to pursue its regulatory submissions, to proceed with its ongoing clinical development activities and to support the preparation for market entry for «Raxone» and «Catena». Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. The complete press release of Santhera
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login

Your Benefits

  • Access to all content
  • Receive newsmails for news and jobs
  • Post ads

myScience